← Leaderboards
Lajos Pusztai
Arizona State University-Tempe Campus
$3,364,076
Attributed
$4,021,548
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $752.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,021,548 · 4
By mechanism
R01$3,843,022 · 3
P30$178,526 · 1
Top collaborators
- Ji Qiu2 shared
Most similar at Arizona State University-Tempe Campus
Same institution · by research overlap
- Ji Qiu$3,239,424
Others in their field
Top investigators on “Validation”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$515,091,456
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- David Heimbrook · Leidos Biomedical Research, Inc.$239,311,963
Research focus
ValidationClinical TrialsProspectiveMalignant NeoplasmsImmunotherapyMalignant Breast NeoplasmTreatment EfficacyGenomicsResearch PersonnelResponseFutureNeoadjuvant TherapyChemotherapySamplingTissuesCohortTranslatingTriple-Negative Invasive Breast CarcinomaProteinsMutationInternationalGenomic DataImmune ResponsePathology
Grant awards (11)
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer$643,798
R01 · FY2025 · CA
Genomics, Genetics and Epigenetics Research Program$97,007
P30 · FY2025 · CA · contact PI
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer$671,146
R01 · FY2024 · CA
Genomics, Genetics and Epigenetics Research Program$81,519
P30 · FY2024 · CA · contact PI
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome$474,931
R01 · FY2020 · CA · contact PI
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome$511,570
R01 · FY2019 · CA · contact PI
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome$419,283
R01 · FY2018 · CA · contact PI
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome$552,594
R01 · FY2017 · CA · contact PI
Preoperative chemotherapy for breast cancer$184,697
R01 · FY2007 · CA · contact PI
preoprative chemotherapy for breast cancer$190,213
R01 · FY2006 · CA · contact PI
Preoperative chemotherapy for breast cancer$194,790
R01 · FY2005 · CA